IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS

Innate-based immunotherapies are becoming increasingly important for treating brain tumor patients. About 50% of WHO grade II and III gliomas carry mutations in IDH1 and ATRX genes. Mutant IDH1 results in the production of 2-hydroxyglutarate, an oncometabolite that promotes global metabolic and epig...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Hariharan, Seethalakshmi, Bowie, Michelle, Hostettler, Janell, Roso, Kristen, He, Yiping, Roskoski, Martin A, Charbonneau, Casey, Keir, Stephen, Brown, Michael, Irvin, David, Zhang, Gao, Gromeier, Matthias, Huse, Jason, Ashley, David
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Immunology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651589/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.448
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares